D
uring the past few decades, the treatment of Crohn's disease (CD) has been advanced by the introduction of several new drug classes as well as multiple novel compounds under development. 1 Recognizing that achievement of endoscopic healing in CD is associated with improved long-term outcomes, treatment targets in both clinical practice and research are evolving from controlling symptoms toward normalization of more objective endpoints including endoscopic, histologic, radiographic, and biomarker measures of inflammation. 2 Regulatory standards for approval of novel CD therapies have also changed, with the U.S. Food and Drug Administration (FDA) now emphasizing the need for achievement of co-primary endpoints that include assessment of validated patientreported outcomes (PROs) in combination with endoscopic healing. 3 These changes in treatment endpoints present unique challenges for clinical development. First, the formal construction and validation of a CD-specific PRO appropriate for use in randomized controlled trials (RCTs) could take years. 4 Second, current endoscopic indices, including the Crohn's Disease Endoscopic Index of Severity (CDEIS) 5 and Simple Endoscopic Score for Crohn's Disease (SES-CD) 6 are too complex for clinical practice, and definitions of endoscopic outcomes have largely been arbitrarily defined. 7 Third, although several radiographic and histologic indices for assessing CD activity have been described, most are insufficiently validated for use in RCTs. 8, 9 Fourth, as novel therapies targeting different components of the immune response are introduced, careful monitoring is required to recognize treatment-specific short-term and long-term adverse events (AEs). Currently, there is no formalized consensus on which efficacy and safety outcomes to measure, what measurement tools should be used, or when selected efficacy and safety outcomes should be assessed in CD RCTs.
To address this unmet need, we have proposed the collaborative development of a core outcome set (COS) for use in CD RCTs. 10 A COS is a consensus-derived minimum set of outcomes that should be measured and reported in all clinical trials of a given disease. 11 Advantages of adopting a COS include reducing heterogeneity in outcome reporting, improving quality of evidence synthesis in meta-analyses and indirect treatment comparisons, and minimizing reporting bias. Selection of outcomes for a COS is a multistep process, starting with a comprehensive review of existing endpoint definitions. 10 Accordingly, we systematically identified the efficacy and safety outcomes reported in placebo-controlled CD RCTs. We aimed to explore the evolution of endpoint reporting in CD trials over time and define the key outcome domains for a conceptual framework for the development of a COS.
Methods

Search Strategy
MEDLINE , EMBASE (1947 EMBASE ( -2017 , and CENTRAL were searched from inception to March 1, 2017 without language restriction. Conference abstracts from Digestive Disease Week and the United European Gastroenterology Week (2012-2016) were reviewed to supplement the search results. Search terms identifying RCTs (including concepts of blinding, randomization, and placebo) in patients with CD were used (Supplementary Table 1 ).
Study Eligibility Criteria
Studies fulfilling the following inclusion criteria were eligible: (1) a placebo-controlled RCT in adult CD patients; (2) medical intervention with aminosalicylate, corticosteroid, immunomodulator, biologic agent, or small molecule therapy; (3) use of the Crohn's Disease Activity Index (CDAI) (Supplementary Table 2) 12 or Harvey-Bradshaw Index (HBI) 13 as enrollment criteria; and (4) duration of at least 2 weeks for induction and 4 months for maintenance trials. Studies evaluating treatment of postoperative CD for recurrence prevention were also eligible. We excluded trials of probiotics, antibiotics, complementary therapies, or devices and trials of hospitalized CD patients. We restricted the inclusion to RCTs incorporating the CDAI or HBI to ensure this review is relevant to modern drug development. Other clinical CD indices are primarily of historical interest.
Data Extraction
Citations for relevant studies were screened independently by 2 investigators (C.E.P., T.M.N). Data extraction was completed independently by 2 investigators (I.M.H., Y.J.A), and disagreements were resolved by consensus. Data extraction included (1) efficacy outcomes (including clinical or composite-clinical, endoscopic, histologic, biomarker, and PROs) and (2) safety outcomes (including occurrence of any AEs, serious AEs requiring hospitalization, drug discontinuation, or persistent or clinically significant disability, deaths, and organ-specific AEs). Clinical-composite outcomes were defined by outcomes including both subjective symptoms and objective assessment (eg, serology). PROs were defined by outcomes directly reported by the patient. Separately published post hoc or retrospective analyses of RCTs were not included to avoid duplicate inclusion.
Data Synthesis and Analysis
A comprehensive inventory of outcomes and definitions was generated through qualitative review. These were organized into outcome subdomains. The proportion of studies reporting each outcome was calculated and stratified by study design (induction vs maintenance vs postoperative prevention) and by decade of publication. Outcome reporting was graphically represented in matrix form, with outcome domains listed in rows and reporting frequency plotted in grayscale gradient over time. Assessment of study quality, risk of bias, and funnel plots for publication bias were not appropriate for this qualitative review, and assessment of item validity, reliability, and responsiveness was outside the scope of this review.
Results
Search Results and Study Characteristics
In total, 11,408 records were identified ( Figure 1 ). The final analysis incorporated 116 studies, of which 81 reported on induction, 44 on maintenance, 14, 22, 24, 25, 47, 58, 67, [72] [73] [74] [75] [76] 83 ,85,88,93-120 and 7 on postoperative prevention trials (Table 1 and Supplementary  Table 3) . 14, [121] [122] [123] [124] [125] [126] There were 35.5% of participants (9677 of 27,263) randomized to placebo. Most trials were phase III studies (38 induction, 35 maintenance, 5 postoperative prevention trials), and a substantial proportion (45.5%) were published after 2006. A biologic agent was the active comparator in 57.8% of RCTs (67/116).
Clinical or Composite-Clinical Efficacy Outcomes and Definitions
Clinical response was reported in 96.3% of induction trials (78/81) and 38.6% of maintenance trials (17/44). Clinical remission was reported in 90.1% of induction trials (73/81) and 36.3% of maintenance trials (16/44) . Sustained, durable, or maintained clinical response or remission at multiple time points was reported in 13 maintenance studies (29.5%). Clinical relapse or worsening was reported in 22 maintenance studies (50.0%).
Clinical recurrence after surgery was reported in 85.7% of postoperative prevention studies (6/7).
The most commonly used assessment tool was the CDAI (96.2%), which was used in 78 induction, 43 maintenance, and 6 postoperative prevention studies (Supplementary Table 4 Fistula response and remission to therapy were defined in 6 induction and 4 maintenance RCTs. Most commonly, response was defined by closure of >50% of draining fistulae, and remission was defined by closure of all draining fistulae, maintained for at least 2 study visits. 37, 38, 44, 49, 54, 79, 109, 113, 114, 116 Endoscopic Efficacy Outcomes and Definitions Twenty-one induction (25.9%), 6 maintenance (13.6%), and 5 postoperative prevention (71.4%) trials reported endoscopic outcomes, primarily in the last 2 decades (Figure 2 ). The most commonly used endoscopic scoring indices were the CDEIS (Supplementary Table 7) . Endoscopic response was previously defined by both absolute (CDEIS !3, SES-CD !2) 68 and by relative (reduction !50-75%) 72,85,87 changes in endoscopic scores from baseline. Thresholds for defining endoscopic remission have ranged from SES-CD or CDEIS scores of 0 to 4; a lower threshold of CDEIS 2 has been used to define endoscopic remission for patients with isolated ileal disease.
72,85,87,89,92,112 Some authors have used separate definitions of mucosal healing, which were based on absence of ulceration in all examined segments. 72, 73, 87, 92, 108 The concept of "deep remission" has also been proposed, incorporating both clinical and endoscopic remission. 87, 92 Although developed as a prognostic tool rather than a measurement of disease activity, the Rutgeerts' score 127 was the most commonly used tool to define postoperative CD recurrence, with most studies defining endoscopic recurrence at the i2 threshold (>5 aphthous lesions with normal mucosa between the lesions or skip areas of larger lesions or lesions confined to the ileocolonic anastomosis). Figure 2 . Proportion of placebo-controlled CD trials reporting key efficacy outcome domains, stratified by year of publication. 
123-126
Other Objective Efficacy Outcomes and Definitions
Histologic outcomes were reported in 9 induction (11.1%), 1 maintenance (2.3%), and 1 postoperative prevention (14.3%) trial (Figure 3 ). The Global Histological Activity Score 30 and its modifications were the most commonly used tools for assessing histologic outcomes 43, 92, 108 (Table 2) . Serum, fecal, or tissue biomarker outcomes were reported in 66 induction (81.5%), 30 maintenance (68.2%), and 3 postoperative prevention (42.9%) trials. The most commonly used biomarker was C-reactive protein (CRP) concentration. In studies published after 2011, RCTs have increasingly used fecal calprotectin as a biomarker endpoint.
70,71,78-82,85-92,117 Most authors did not specify thresholds for biomarker response and remission; instead, median, mean, or percent changes in pre-treatment and post-treatment biomarker concentrations were reported. Exploratory tissue biomarker outcomes, including tissue receptor or cytokine expression and immunohistochemistry endpoints, were described in 4 trials (3.6%).
29,33,52,87 The proportion of studies reporting biomarker endpoints has increased during the past 2 decades (Figure 2 ). 
Patient-reported Outcomes and Definitions
Discussion
Endpoints for clinical trials in CD are shifting, driven by the emphasis on achieving objective improvements in inflammatory burden in addition to symptom control. 2 In this systematic review of all placebo-controlled RCTs of major therapeutic classes for CD, we demonstrate the marked heterogeneity in definitions of clinical response, remission, and loss of response. One of the most important observations was that 38 different definitions of clinical response or remission were used. We provide a comprehensive appraisal of endoscopic, histologic, biomarker, and patient-reported efficacy and safety outcomes used in the literature, which establishes a framework by which a COS for CD RCTs can be developed. 10 Although the CDAI has been the most widely used measure of clinical disease activity in CD RCTs, it is no longer accepted as a primary efficacy endpoint in clinical development by the U.S. FDA or European Medicines Agency. The CDAI insufficiently discriminates functional from inflammatory disease, was not developed and scaled according to modern biometric principles for index development, and is not reflective of endoscopic 134 CCR was introduced as the primary outcome in the PURSUIT maintenance trial of golimumab for UC. Patients with CCR, defined by sustained response without treatment failure through 54 weeks, assessed by every 4-week partial Mayo score and full Mayo score at weeks 30 and 54, were more likely to have endoscopic healing (90.4% vs 2.6%) and normal QoL (75% vs 24.4%). 135 This rigorous clinical evaluation would be too cumbersome for routine practice without an easy-to-use, valid, and responsive PRO, but the concept of continuously monitoring patient outcomes and targeting continuous disease control offers an opportunity for possible long-term disease modification.
Looking beyond symptom control, achievement of endoscopic healing in CD is associated with disease modification. The uptake of endoscopic outcomes in CD RCTs lags behind the use of endoscopy in UC trials. 136 This may be driven by the need for complete ileocolonoscopy to evaluate the patchy nature of CD as compared with sigmoidoscopy for UC. Additional drawbacks to both the CDEIS and SES-CD include their complexity, underestimated disease activity when the bowel is incompletely visualized, and conflicting opinions regarding how to best score fibrostenotic versus inflammatory strictures. Finally, although both scores demonstrate substantial intra-rater and inter-rater reliability and responsiveness to therapy, 137,138 the definitions of endoscopic outcomes are heterogeneous and arbitrarily determined. Vuitton et al 139 have proposed using a >50% decrease in SES-CD or CDEIS for the definition of endoscopic response, SES-CD of 0-2 for endoscopic remission, and Rutgeerts' score i0-i1 for endoscopic remission after surgery. These definitions have not been uniformly adopted, and the SES-CD 0-2 criteria for remission may be too restrictive and unachievable with agents that appear to confer endoscopic benefit.
Endoscopy incompletely defines transmural structural bowel damage and extraluminal disease; in clinical practice, magnetic resonance (MR), computed tomography, and ultrasound can noninvasively measure transmural inflammation, strictures, fistulae, abscesses, and proximal small bowel involvement. Sensitivity and specificity of MR enterography for active inflammation exceed 90%, and thus, its use as a tool for assessing RCT inclusion and outcome criteria is of interest.
140 Pelvic MR imaging is also highly sensitive for evaluation of perianal fistulizing disease and has been used to evaluate fistula response in an RCT of mesenchymal stem cells. 141 Multiple MR scoring systems have been developed, including the MR Index of Activity Score, London Score, MR Enterography Global Score, Nancy Score, and ClermontFerrand Index. 8 The lack of complete validation, proven responsiveness to treatment, and standardized definitions of radiographic response has precluded the routine use of these indices in RCTs to date.
Similarly, there has been a paucity of histologic endpoints reported in CD RCTs. Although many histologic indices for CD have been proposed, most are not validated and inadequate for use as outcome criteria in RCTs. 9 Questions regarding when, where, and how to biopsy in CD remain unresolved. These issues are further compounded in patients with active inflammation in locations inaccessible to standard ileocolonoscopy. Despite these challenges, the adoption of radiographic and histologic assessment presents an opportunity to advance the direction of CD trials toward targeting disease modification. One potential tool for assessing this is the Lémann Index, which incorporates surgical resection and diagnostic imaging modalities to consider damage location, severity, extent, progression, and reversibility.
142
The invasive nature of endoscopic and histologic assessment has driven an increasing interest in using biomarkers as treatment endpoints. CD trials have routinely incorporated serum biomarkers, including CRP. However, CRP has poor sensitivity for active inflammation because up to one-third of patients do not mount a CRP response. 143 Fecal calprotectin has emerged in the last decade as a stool biomarker. Although there are potential limitations to using fecal calprotectin in ileal CD, a recent open-label RCT that compared a tight control treatment algorithm driven by targeting fecal calprotectin <250 mg/g and CRP <5 mg/L in addition to CDAI <150 resulted in greater rates of mucosal healing than a strategy based on symptom control alone. 144 Several novel biomarkers are also in development, including matrix metallopeptidase 9 and interleukin 22.
145
Our study has some limitations. First, we included only placebo-controlled RCTs of major therapeutic classes. However, this design is the gold standard for regulatory approval. Furthermore, although we recognize that antibiotics have an important role in perianal fistulizing CD, this is outside the scope of both this review and the COS. Second, we restricted the search to studies using the CDAI or HBI as inclusion criteria to focus the review on contemporary and currently relevant outcomes. Third, we could not account for study publication bias; it is possible that additional outcomes of interest in unpublished negative RCTs have been uncaptured. Finally and importantly, evaluation of the content, construct, and criterion validity, reliability, and responsiveness of these outcome measures was outside the scope of this article. Careful consideration of these parameters will be important for determining which outcomes should be included in a COS. Validity, reliability, and responsiveness measures have been more rigorously reviewed previously for PROs, 132 histology endpoints, 9 and endoscopy scores. 7 In conclusion, this review highlights the surge in clinical trial research in CD during the past 40 years, with multiple therapeutic classes under development. The marked heterogeneity in outcome definitions and rapidly evolving landscape of treatment endpoints in CD highlight the need for standardization, which can be achieved through a consensus on core outcomes for use in future RCTs. The next step in the development of a COS involves prioritizing and ratifying outcomes by using a Delphi method. 10 Selecting relevant outcomes for CD RCTs requires input from multiple stakeholders, including patients, clinicians, researchers, and industry. This review serves as the conceptual framework for prioritizing existing endpoints and anticipating future directions in CD research for a COS. We anticipate that a COS in this field will incorporate patient-reported, endoscopic, histologic, and biomarker outcomes, stratified by induction and maintenance endpoints.
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